| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 151, 1649-1654, Copyright © 1997 by American Society for Investigative Pathology
REGULAR ARTICLES |
AO Stemmer-Rachamimov, L Xu, C Gonzalez-Agosti, JA Burwick, D Pinney, R Beauchamp, LB Jacoby, JF Gusella, V Ramesh and DN Louis
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
NF2 (neurofibromatosis 2, encoding the merlin protein) gene mutations and chromosome 22q loss have been demonstrated in the majority of sporadic and NF2-associated schwannomas, but many schwannomas fail to demonstrate genetic evidence of biallelic NF2 gene inactivation. In addition, the role of the merlin-related ERM family members (ezrin, radixin, and moesin) remains unclear in these tumors. We therefore studied expression of NF2-encoded merlin as well as ezrin, radixin, and moesin in 22 vestibular and peripheral schwannomas that had been evaluated for NF2 mutations and chromosome 22q loss. Western blotting and immunohistochemistry with antibodies directed against the amino and carboxy termini of merlin demonstrated loss of merlin expression in all studied schwannomas, including 12 tumors lacking genetic evidence of biallelic NF2 gene inactivation. Western blotting with antibodies directed against ezrin, radixin, and moesin, however, showed expression of these proteins in all schwannomas. In addition, immunohistochemistry with an antibody to moesin revealed widespread expression in tumor and endothelial cells. These data indicate that the specific loss of merlin is universal to schwannomas and is not linked to loss of ezrin, radixin, or moesin expression.
This article has been cited by other articles:
 |
|
 |
|
  A. I. McClatchey and M. Giovannini Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin Genes & Dev., October 1, 2005; 19(19): 2265 - 2277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M E Baser, L Kuramoto, R Woods, H Joe, J M Friedman, A J Wallace, R T Ramsden, S Olschwang, E Bijlsma, M Kalamarides, et al. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2 J. Med. Genet., July 1, 2005; 42(7): 540 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. MacCollin, E. A. Chiocca, D. G. Evans, J. M. Friedman, R. Horvitz, D. Jaramillo, M. Lev, V. F. Mautner, M. Niimura, S. R. Plotkin, et al. Diagnostic criteria for schwannomatosis Neurology, June 14, 2005; 64(11): 1838 - 1845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Kaufman, B. S. Heinrich, C. Willett, A. Perry, F. Finseth, R. A. Sobel, and M. MacCollin Somatic Instability of the NF2 Gene in Schwannomatosis Arch Neurol, September 1, 2003; 60(9): 1317 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. MacCollin, C. Willett, B. Heinrich, L. B. Jacoby, J. S. Acierno Jr., A. Perry, and D. N. Louis Familial schwannomatosis: Exclusion of the NF2 locus as the germline event Neurology, June 24, 2003; 60(12): 1968 - 1974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gautreau, J. Manent, B. Fievet, D. Louvard, M. Giovannini, and M. Arpin Mutant Products of the NF2 Tumor Suppressor Gene Are Degraded by the Ubiquitin-Proteasome Pathway J. Biol. Chem., August 23, 2002; 277(35): 31279 - 31282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-M. Bashour, J.-J. Meng, W. Ip, M. MacCollin, and N. Ratner The Neurofibromatosis Type 2 Gene Product, merlin, Reverses the F-Actin Cytoskeletal Defects in Primary Human Schwannoma Cells Mol. Cell. Biol., February 15, 2002; 22(4): 1150 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Gutmann, A. C. Hirbe, and C. A. Haipek Functional analysis of neurofibromatosis 2 (NF2) missense mutations Hum. Mol. Genet., July 1, 2001; 10(14): 1519 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Gutmann The neurofibromatoses: when less is more Hum. Mol. Genet., April 1, 2001; 10(7): 747 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lasota, J. F. Fetsch, A. Wozniak, B. Wasag, R. Sciot, and M. Miettinen The Neurofibromatosis Type 2 Gene Is Mutated in Perineurial Cell Tumors : A Molecular Genetic Study of Eight Cases Am. J. Pathol., April 1, 2001; 158(4): 1223 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sainio, J. Jaaskelainen, H. Pihlaja, and O. Carpen Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus Neurology, March 14, 2000; 54(5): 1132 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Goutebroze, E. Brault, C. Muchardt, J. Camonis, and G. Thomas Cloning and Characterization of SCHIP-1, a Novel Protein Interacting Specifically with Spliced Isoforms and Naturally Occurring Mutant NF2 Proteins Mol. Cell. Biol., March 1, 2000; 20(5): 1699 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ueki, C. Wen-Bin, Y. Narita, A. Asai, and T. Kirino Tight Association of Loss of Merlin Expression with Loss of Heterozygosity at Chromosome 22q in Sporadic Meningiomas Cancer Res., December 1, 1999; 59(23): 5995 - 5998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. den Bakker, K. J. Vissers, A. C. Molijn, J. M. Kros, E. C. Zwarthoff, and T. H. van der Kwast Expression of the Neurofibromatosis Type 2 Gene in Human Tissues J. Histochem. Cytochem., November 1, 1999; 47(11): 1471 - 1480. [Abstract] [Full Text]
|
|
|
|
|
|
M. Giovannini, E. Robanus-Maandag, M. Niwa-Kawakita, M. van der Valk, J. M. Woodruff, L. Goutebroze, P. Merel, A. Berns, and G. Thomas Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein Genes & Dev., April 15, 1999; 13(8): 978 - 986. [Abstract] [Full Text]
|
|
|
|
 |
|
 M Gronholm, M Sainio, F Zhao, L Heiska, A Vaheri, and O Carpen Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin J. Cell Sci., January 3, 1999; 112(6): 895 - 904. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
